Syros Pharmaceuticals, Inc.

NasdaqGS:SYRS Stock Report

Market Cap: US$151.9m

Syros Pharmaceuticals Future Growth

Future criteria checks 6/6

Syros Pharmaceuticals is forecast to grow earnings and revenue by 59.1% and 52.9% per annum respectively. EPS is expected to grow by 61.4% per annum. Return on equity is forecast to be 105% in 3 years.

Key information

59.1%

Earnings growth rate

61.4%

EPS growth rate

Biotechs earnings growth20.6%
Revenue growth rate52.9%
Future return on equity105.0%
Analyst coverage

Low

Last updated27 Mar 2024

Recent future growth updates

Recent updates

Syros Pharmaceuticals: Rising Despite Dilution, A Must Look

Jan 14

Syros Pharmaceuticals: A Major Vote Of Confidence From Insiders

Sep 20

Syros gets FDA orphan drug designation for pancreatic cancer treatment SY-5609

Sep 13

Syros Pharmaceuticals Q2 2022 Earnings Preview

Aug 08

Syros Pharmaceuticals Is A Buy As New Trials Start

Nov 20

Syros Pharmaceuticals (NASDAQ:SYRS) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Nov 08
Syros Pharmaceuticals (NASDAQ:SYRS) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Syros Pharmaceuticals, Inc.'s (NASDAQ:SYRS) CEO Will Probably Find It Hard To See A Huge Raise This Year

Jun 02
Syros Pharmaceuticals, Inc.'s (NASDAQ:SYRS) CEO Will Probably Find It Hard To See A Huge Raise This Year

Syros Pharma up 18% day after ARK Innovation dumps shares

May 27

Analysts Just Made A Substantial Upgrade To Their Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Forecasts

May 11
Analysts Just Made A Substantial Upgrade To Their Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Forecasts

Does Syros Pharmaceuticals (NASDAQ:SYRS) Have A Healthy Balance Sheet?

May 07
Does Syros Pharmaceuticals (NASDAQ:SYRS) Have A Healthy Balance Sheet?

Can You Imagine How Syros Pharmaceuticals' (NASDAQ:SYRS) Shareholders Feel About The 57% Share Price Increase?

Mar 02
Can You Imagine How Syros Pharmaceuticals' (NASDAQ:SYRS) Shareholders Feel About The 57% Share Price Increase?

What Kind Of Investors Own Most Of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS)?

Jan 26
What Kind Of Investors Own Most Of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS)?

Earnings and Revenue Growth Forecasts

NasdaqGS:SYRS - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202624332N/AN/A2
12/31/202582-112N/AN/A2
12/31/20246-122N/AN/A3
12/31/202310-165-110-110N/A
9/30/20239-105-123-122N/A
6/30/20239-95-127-126N/A
3/31/202312-93-131-130N/A
12/31/202215-95-124-123N/A
9/30/202223-114-116-115N/A
6/30/202225-109-108-107N/A
3/31/202224-97-109-108N/A
12/31/202123-87-101-100N/A
9/30/202121-93-108-106N/A
6/30/202120-86-95-94N/A
3/31/202118-81-81-80N/A
12/31/202015-84-61-57N/A
9/30/202010-74-50-38N/A
6/30/20207-74-48-34N/A
3/31/20204-76-54-40N/A
12/31/20192-75-73-60N/A
9/30/20192-74-68-63N/A
6/30/20192-70-65-62N/A
3/31/20192-64-60-58N/A
12/31/20182-62-42-40N/A
9/30/20181-60-38-37N/A
6/30/20181-58-37-37N/A
3/31/20180-57-35-34N/A
12/31/20171-54-46-45N/A
9/30/20171-50N/A-44N/A
6/30/20171-50N/A-43N/A
3/31/20171-51N/A-43N/A
12/31/20160-51N/A-41N/A
9/30/2016N/A-52N/A-39N/A
6/30/2016N/A-48N/A-35N/A
3/31/20160-41N/A-30N/A
12/31/20150-35N/A-23N/A
9/30/20150-28N/A-18N/A
12/31/2014N/A-16N/A-12N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SYRS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).

Earnings vs Market: SYRS is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: SYRS is expected to become profitable in the next 3 years.

Revenue vs Market: SYRS's revenue (52.9% per year) is forecast to grow faster than the US market (8.2% per year).

High Growth Revenue: SYRS's revenue (52.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: SYRS's Return on Equity is forecast to be very high in 3 years time (105%).


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.